Serum sphingosine negatively correlates with albumin predicting the risk of hepatocellular carcinoma
Jazyk angličtina Země Česko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
31074463
DOI
10.5507/bp.2019.015
Knihovny.cz E-zdroje
- Klíčová slova
- HCC, albumin, serum sphingolipid,
- MeSH
- alfa-fetoproteiny metabolismus MeSH
- hepatocelulární karcinom krev komplikace diagnóza patologie MeSH
- jaterní cirhóza krev komplikace MeSH
- lidé středního věku MeSH
- lidé MeSH
- mnohočetné primární nádory krev komplikace diagnóza MeSH
- nádory jater krev komplikace diagnóza patologie MeSH
- riziko MeSH
- ROC křivka MeSH
- sérový albumin metabolismus MeSH
- sfingosin krev MeSH
- studie případů a kontrol MeSH
- tumor burden MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- alfa-fetoproteiny MeSH
- sérový albumin MeSH
- sfingosin MeSH
BACKGROUND: The roles of sphingosine in various cancers have not been fully investigated. Our aim was to identify the relationship between serum sphingosine and the risk of hepatocellular carcinoma (HCC). METHODS: Serum sphingosine in 34 normal people and 73 HCC patients were reviewed retrospectively. Receiver operating characteristic curve analysis was performed to determine the cut-off values of sphingosine in the serum. Chi-square test, t test and regression analysis were used to test the association between serum sphingosine and individual clinicopathologic parameters. RESULTS: Serum sphingosine was higher in HCC patients (155.91±331.5 ng/mL) with normal persons as the control (30.92±29.4 ng/mL). The sphingosine threshold according to ROC curve was set at 22.5 ng/mL with a sensitivity of 74%, and a specificity of 55.9%. Meanwhile, sphingosine in HCC patients with abnormal albumin was significantly higher than that in patients with normal albumin (t=2.452, P=0.019). When HCC patients were divided into two groups serum sphingosine was negatively associated with albumin in HCC patients (χ2=4.469, P=0.035). Moreover, the logistic regression analysis showed that large tumor size (P=0.018, OR=0.13) and a low albumin (P=0.005, OR=8.856) were two independent risk factors for serum sphingosine upregulation. High AFP coupled with high serum sphingosine, high sphingosine and high AFP respectively were found in 91.2%, 75.4%, 73% of the HCC patients. CONCLUSIONS: These results suggest that serum sphingosine could be treated as a marker for the risk of HCC. AFP and sphingosine in the serum could be used together for HCC diagnosis.
Citace poskytuje Crossref.org
